Neuroimaging Techniques: Researchers use tools like SPECT (Single Photon Emission-Computed Tomography) or fMRI to measure regional cerebral blood flow (rCBF) as a proxy for brain activity.
Cognitive Challenges: Tasks like the Wisconsin Card Sorting Test (WCST) are used to measure executive function and frontal lobe activity during research trials.
Pharmacological Manipulation: Administering drugs like amphetamines (dopamine agonists) allows researchers to observe how increasing neurotransmitter levels affects brain function and cognitive performance.
Controlled Experiments: Studies often use a placebo-controlled design to ensure that observed changes in brain activity are due to the chemical intervention rather than participant expectations.
| Feature | Positive Symptoms | Negative Symptoms |
|---|---|---|
| Nature | Addition of abnormal behaviors | Loss of normal behaviors |
| Examples | Hallucinations, Delusions | Social withdrawal, Flat affect |
| Brain Link | Overactive dopamine in subcortical areas | Underactive dopamine in prefrontal cortex |
| Treatment | Often responsive to antipsychotics | Harder to treat with standard medication |
Agonists vs. Antagonists: Agonists (like amphetamines) stimulate or mimic neurotransmitters, while antagonists (like haloperidol) block their receptors to reduce activity.
Structural vs. Functional Abnormalities: Structural research looks at physical brain size (e.g., enlarged ventricles), while functional research looks at how the brain operates (e.g., blood flow during a task).
Evaluate Sample Sizes: Many biological studies in schizophrenia use very small samples (e.g., 10-15 people), which limits the generalizability of the findings to the wider population.
Identify Cause and Effect: Always check if a study can prove that brain differences cause schizophrenia, or if the brain changes are a result of the disorder or long-term medication use.
Check for Cultural Bias: Research conducted in a single geographic or ethnic group may not apply globally, as schizophrenia rates and symptoms can vary across cultures.
Ethical Considerations: Be prepared to discuss the ethics of giving potentially harmful substances (like amphetamines) to vulnerable patients or using placebos that offer no therapeutic benefit.
